PYPD
Polypid Ltd

832
Mkt Cap
$57.23M
Volume
77,073.00
52W High
$3.93
52W Low
$2.30
PE Ratio
-1.21
PYPD Fundamentals
Price
$3.63
Prev Close
$3.60
Open
$3.61
50D MA
$3.50
Beta
0.40
Avg. Volume
89,729.35
EPS (Annual)
-$4.91
P/B
2.39
Rev/Employee
$0.00
Loading...
Loading...
News
all
press releases
FY2025 Earnings Forecast for PolyPid Issued By HC Wainwright
PolyPid Ltd. (NASDAQ:PYPD - Free Report) - Equities research analysts at HC Wainwright decreased their FY2025 EPS estimates for PolyPid in a research note issued on Wednesday, November 12th. HC...
MarketBeat·4d ago
News Placeholder
More News
News Placeholder
Roth Capital Issues Optimistic Estimate for PolyPid Earnings
PolyPid Ltd. (NASDAQ:PYPD - Free Report) - Stock analysts at Roth Capital raised their FY2025 EPS estimates for PolyPid in a research report issued on Thursday, November 13th. Roth Capital analyst B...
MarketBeat·4d ago
News Placeholder
Wall Street Zen Upgrades PolyPid (NASDAQ:PYPD) to Hold
Wall Street Zen raised PolyPid from a "sell" rating to a "hold" rating in a report on Sunday...
MarketBeat·5d ago
News Placeholder
PolyPid Ltd. (NASDAQ:PYPD) Given Consensus Recommendation of "Moderate Buy" by Analysts
PolyPid Ltd. (NASDAQ:PYPD - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the seven brokerages that are currently covering the firm, MarketBeat.com reports. One...
MarketBeat·6d ago
News Placeholder
Roth Capital Lowers PolyPid (NASDAQ:PYPD) Price Target to $9.00
Roth Capital lowered their price target on PolyPid from $10.00 to $9.00 and set a "buy" rating for the company in a report on Thursday...
MarketBeat·6d ago
News Placeholder
PolyPid (NASDAQ:PYPD) Issues Earnings Results, Beats Estimates By $0.17 EPS
PolyPid (NASDAQ:PYPD - Get Free Report) posted its earnings results on Wednesday. The company reported ($0.37) EPS for the quarter, beating analysts' consensus estimates of ($0.54) by $0.17...
MarketBeat·7d ago
News Placeholder
PolyPid Ends Equity Sales Agreement, No Penalties Incurred
PolyPid (PYPD) has released an update. PolyPid Ltd. has officially notified Cantor Fitzgerald of its decision to end their Controlled Equity Offeri...
TipRanks Financial Blog·1y ago
News Placeholder
PolyPid to Participate in Barclays 26th Annual Global Healthcare Conference
PETACH TIKVA,Israel, Feb. 28, 2024 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), ( PolyPid or the Company ), a late-stage biopharma company aiming to improve surgical outcomes, today...
Globe Newswire·2y ago
News Placeholder
PolyPid GAAP EPS of -$3.97 misses by $1.18
PolyPid GAAP EPS of -$3.97 misses by $1.18...
SeekingAlpha.com: All News·2y ago
News Placeholder
PolyPid Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
More Than 100 Patients Enrolled in Ongoing SHIELD II Phase 3 Trial of D-PLEX100 for the Prevention of Abdominal Colorectal Surgical Site Infections Unblinded Interim Analysis to be Conducted Once...
Globe Newswire·2y ago

Latest PYPD News

View

Advertisement|Remove ads.

Advertisement|Remove ads.